Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019

Abstract The longevity of patients with chronic lymphocytic leukemia (CLL) has improved progressively over the past decades, making it essential to understand long-term health outcomes, such as second primary malignancies (SPMs). Therefore, this nationwide, population-based study assessed the risk o...

Full description

Bibliographic Details
Main Authors:	Lina van der Straten, Mark-David Levin, Manette A. W. Dinnessen, Otto Visser, Eduardus F. M. Posthuma, Jeanette K. Doorduijn, Anton W. Langerak, Arnon P. Kater, Avinash G. Dinmohamed
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-01-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00784-z

Similar Items

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
by: Lina van derStraten, et al.
Published: (2024-11-01)

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018
by: Lina van der Straten, et al.
Published: (2022-04-01)

Conditional relative survival among patients with chronic lymphocytic leukaemia: A population‐based study in the Netherlands
by: Lina van derStraten, et al.
Published: (2022-02-01)

PB1886: LONG-TERM TRENDS IN THE LOSS OF LIFE EXPECTANCY AFTER A DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018
by: L. Van Der Straten, et al.
Published: (2022-06-01)

Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands
by: Manette A. W. Dinnessen, et al.
Published: (2021-01-01)

Treatment and Survival of Patients With Primary Effusion Lymphoma in the Netherlands
by: Avinash G. Dinmohamed, et al.
Published: (2018-10-01)

P644: THE LIFE EXPECTANCY OF PATIENTS WITH HAIRY CELL LEUKEMIA VERGES UPON THE LIFE EXPECTANCY OF THE GENERAL POPULATION: A POPULATION-BASED STUDY IN THE NETHERLANDS
by: A. Dinmohamed, et al.
Published: (2022-06-01)

Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
by: Matthijs van der Meulen, et al.
Published: (2020-04-01)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
by: Manette A.W. Dinnessen, et al.
Published: (2020-11-01)

Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands
by: Stefanie Slot, et al.
Published: (2021-07-01)

Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015
by: Avinash G. Dinmohamed, et al.
Published: (2017-09-01)

Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019Research in context
by: Carolien C.H.M. Maas, et al.
Published: (2023-06-01)

Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands
by: Elise R. A. Pennings, et al.
Published: (2024-01-01)

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989–2010
by: Djamila E. Issa, et al.
Published: (2015-04-01)

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
by: Marco V. Haselager, et al.
Published: (2020-10-01)

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
by: Iris de Weerdt, et al.
Published: (2019-06-01)

P1139: COMPARISON OF 6XR-CHOP21 VERSUS 6XR-CHOP+2R FOR ADVANCED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A PROPENSITY SCORE WEIGHTED POPULATION-BASED ANALYSIS
by: Carolien Maas, et al.
Published: (2023-08-01)

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
by: Arnon P. Kater, et al.
Published: (2019-01-01)

Large granular lymphocyte cells and immune dysregulation diseases – the chicken or the egg?
by: Anton W. Langerak, et al.
Published: (2018-02-01)

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
by: Martijn HA van Attekum, et al.
Published: (2017-09-01)

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
by: Fleur S. Peters, et al.
Published: (2021-03-01)

Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?
by: Hester F Lingsma, et al.
Published: (2024-07-01)

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
by: Paul Hengeveld, et al.
Published: (2023-08-01)

Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab
by: Arnon P. Kater, et al.
Published: (2020-07-01)

Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA
by: Erik Slinger, et al.
Published: (2016-09-01)

Towards regionally forecasting shallow subsidence in the Netherlands
by: T. Candela, et al.
Published: (2020-04-01)

Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
by: Carolien C. H. M. Maas, et al.
Published: (2024-09-01)

P601: GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSIS
by: Pieter Martijn Kolijn, et al.
Published: (2023-08-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
by: Ruth Wester, et al.
Published: (2022-02-01)

Poverty and union formation among never-married single mothers in the Netherlands 1989-2005
by: Monden, C, et al.
Published: (2010)

Corrigendum: Dermatofibrosarcoma Protuberans Re-excision and Recurrence Rates in the Netherlands Between 1989 and 2016
by: Charlotte B. van Lee, et al.
Published: (2022-08-01)

Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia
by: Blaž Oder, et al.
Published: (2023-04-01)

P593: T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
by: Chiara Montironi, et al.
Published: (2023-08-01)

Rural land uses and planning : a comparative study of the Netherlands and the United States /
by: 254011 Held, R. Burnell, et al.

Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia
by: Iris de Weerdt, et al.
Published: (2016-11-01)

Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia
by: Zhenghao Chen, et al.
Published: (2023-07-01)

ACVIM consensus statement guidelines on diagnosing and distinguishing low‐grade neoplastic from inflammatory lymphocytic chronic enteropathies in cats
by: Sina Marsilio, et al.
Published: (2023-05-01)

P595: DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
by: Helga Simon-Molas, et al.
Published: (2023-08-01)

Malignant extracranial germ cell tumors in the Netherlands between 1990 and 2018: Stable incidence and improved survival
by: Caroline C.C. Hulsker, et al.
Published: (2024-06-01)